Compare General Motors Company (GM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Medpace Holdings Inc — how do they compare? General Motors Company trades at $87.13 (market cap $78.40B), while Medpace Holdings Inc trades at $599.34 (market cap $16.90B). The key difference: General Motors Company is far larger — about 4.6× Medpace Holdings Inc's market cap, and General Motors Company pays a 0.81% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GM | MEDP | |
|---|---|---|
Market Cap | $78.40B | $16.90B |
Sector | Consumer Cyclical | Technology |
52-Week High | $90.30 | $620.59 |
52-Week Low | $54.16 | $393.42 |
Enterprise Value | $181.38B | $16.52B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.74, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company has demonstrated consistent earnings outperformance, beating estimates in the last three quarters. Recent strategic moves include a $4.5 billion parts supply deal and extending its China joint venture for 20 years. Valuation metrics show attractive P/S and P/B ratios, though profitability margins remain thin with net income margin at 1.05%.
GM presents a compelling investment case with analyst consensus pointing to 24% upside to the $108.82 price target. Strong cash flow generation and strategic partnerships support growth prospects, but investors face risks from declining profit margins, rising debt levels, and automotive industry cyclicality. The stock's current technical positioning near key support levels suggests potential for near-term stability.
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
